- The FDA's Oncologic Drugs Advisory Committee meets today to review and discuss Spectrum Pharmaceuticals' (NASDAQ:SPPI) New Drug Application (NDA) seeking approval of apaziquone, branded as Qapzola, for the immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer.
- Draft questions
- FDA briefing doc
- Spectrum briefing doc
- Update: The panel voted 14 - 0 against approval.
Ad Comm review today for Spectrum Pharma's apaziquone
Recommended For You
About ASRT Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| ASRT | - | - |
| Assertio Holdings, Inc. | ||